HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
2016年9月9日 更新者：Hoffmann-La Roche
A Randomized, Open-Label, Multicenter, Parallel Group Study Evaluating the Efficacy and Safety of 135 μg and 90 μg of PEGASYS® Given as Monotherapy to Patients With Chronic Hepatitis C and End-Stage Renal Disease Undergoing Hemodialysis
This study evaluated the safety and efficacy of peginterferon alfa-2a monotherapy in participants with Chronic Hepatitis C (CHC) who have End-Stage Renal Disease (ESRD) and were undergoing hemodialysis.
研究概览
研究类型
介入性
注册 (实际的)
81
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
-
Medan、印度尼西亚、20119
-
-
-
-
-
Graz、奥地利、8036
-
Wien、奥地利、1090
-
-
-
-
-
Brasilia、巴西、70335-000
-
Porto Alegre、巴西、90035-003
-
Sao Jose Rio Preto、巴西、15090-003
-
Sao Luis、巴西、78048-790
-
Sao Paulo、巴西、04023-900
-
-
-
-
-
Athens、希腊、11527
-
Nikea、希腊、18354
-
-
-
-
-
Cagliari、意大利、09134
-
-
-
-
-
Creteil、法国、94010
-
Le Kremlin-bicetre、法国、94275
-
Marseille、法国、13385
-
Paris、法国、75747
-
Strasbourg、法国、67091
-
Toulouse、法国、31059
-
-
-
-
-
Istanbul、火鸡、34303
-
Istanbul、火鸡、34390
-
Istanbul、火鸡、34662
-
Izmir、火鸡、35040
-
-
-
-
-
Abu Dhabi、阿拉伯联合酋长国
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 65年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Serum hepatitis C virus ribonucleic acid (HCV RNA) quantifiable at greater than (>) 600 IU/mL
- Liver biopsy consistent with chronic hepatitis C infection obtained within 2 years of enrollment
- Compensated liver disease without cirrhosis
- Participants with end-stage renal disease undergoing hemodialysis
- Negative serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
- All fertile participants must have been using effective contraception during treatment with study drug
Exclusion Criteria:
- Interferon therapy at any previous time
- Liver cirrhosis
- Signs and symptoms of hepatocellular carcinoma
- History or other evidence of decompensated liver disease
- Any investigational drug less than or equal to 6 weeks prior to the first dose of study drug
- History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures)
- Poorly controlled diabetes
- Thyroid dysfunction not adequately controlled
- Evidence of severe retinopathy or clinically relevant ophthalmological disorder
- Severe hyperparathyroidism defined as intact Parathyroid Hormone (PTH) > 800 picogram/milliliter (pg/mL)
- Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment ≤ 6 months prior to the first dose of study drug
- Acute renal failure
- Women with ongoing pregnancy or breast feeding
- Positive test at screening for anti-HAV IgM Ab (hepatitis A virus immunoglobulin M antibody), hepatitis B surface antigen (HBsAg), anti-HBc (hepatitis B core) IgM Ab, anti-HIV (human immunodeficiency virus) Ab
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Peginterferon alfa-2a 135 microgram (mcg)
Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 135 mcg subcutaneously (SC) once weekly up to Week 48.
|
Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
其他名称：
|
|
实验性的：Peginterferon alfa-2a 90 mcg
Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 90 mcg SC once weekly up to Week 48.
|
Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment
大体时间：24 weeks after end of treatment (Week 72)
|
SVR was defined as the percentage of patients with undetectable HCV RNA.
SVR rate was calculated as the number of participants with an undetectable HCV RNA divided by the number of participants of the respective participant population.
The last single HCV RNA less than (<) 50 international units per millilitre (IU/mL) measured >=140 days after treatment end (i.e., >= 20 weeks after treatment end) was used to determine SVR.
Participants without measurements in this time window were considered to be nonresponders.
|
24 weeks after end of treatment (Week 72)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants With Virological Response (Non-detectable Hepatitis C Virus-ribonucleic Acid [HCV RNA]) at End of Treatment (EOT)
大体时间：EOT (Week 48)
|
Virological response at the end of study treatment was defined as the percentage of participants with undetectable HCV RNA.
This response rate at end of treatment was calculated as the number of participants with undetectable HCV RNA divided by the number of participants of the respective participant population.
|
EOT (Week 48)
|
|
Percentage of Participants With Virological Response (at Least a 2-log 10 Decrease in HCV RNA as Compared With Baseline or Unquantifiable [Less Than {<} 600 International Unit/Milliliter {IU/mL}] or Undetectable HCV RNA [< 50 IU/mL]) at Week 12 and 24
大体时间：Weeks 12 and 24
|
Virological response at Weeks 12 and 24 was computed as the percentage of participants with at least a 2-log 10 decrease in HCV RNA at Weeks 12 and 24 as compared with baseline or with an unquantifiable (< 600 IU/mL) or an undetectable HCV RNA test result (< 50 IU/mL) at Week 12 and at Week 24, calculated as the number of participants meeting this criterion divided by the number of participants of the respective participant population.
|
Weeks 12 and 24
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2004年6月1日
初级完成 (实际的)
2007年8月1日
研究完成 (实际的)
2007年8月1日
研究注册日期
首次提交
2016年6月16日
首先提交符合 QC 标准的
2016年6月16日
首次发布 (估计)
2016年6月20日
研究记录更新
最后更新发布 (估计)
2016年10月31日
上次提交的符合 QC 标准的更新
2016年9月9日
最后验证
2016年9月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.